Skip Navigation


QJM Advance Access originally published online on August 8, 2005
QJM 2005 98(10):765-769; doi:10.1093/qjmed/hci111
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
98/10/765    most recent
hci111v2
hci111v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Struthers, A.D.
Right arrow Articles by Davies, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Struthers, A.D.
Right arrow Articles by Davies, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Commentary

B-type natriuretic peptide: a simple new test to identify coronary artery disease?

A.D. Struthers and J. Davies

From the Division of Medicine & Therapeutics, Ninewells Hospital & Medical School, Dundee, UK

Address correspondence to Professor A.D. Struthers, Division of Medicine & Therapeutics, Ninewells Hospital & Medical School, Dundee DD1 9SY. email: a.d.struthers{at}dundee.ac.uk

A common key question in clinical medicine is whether coronary artery disease (CAD) is present in a patient. This applies not only to patients with symptomatic chest pain, but also to those at high risk of sudden unexpected death due to asymptomatic CAD, such as diabetics. In both groups of patients, it would be of great benefit if a simple blood test could identify those most likely to have CAD. Such individuals could then be selected for more definitive but more invasive tests for CAD, such as angiography, exercise testing, etc. In addition to its established role in diagnosing heart failure, it appears that BNP may fulfil this function of pre-screening for both symptomatic and asymptomatic CAD. We review the evidence for this new prospect, which has the potential to reduce cardiac deaths by using a simple blood test to better target cardioprotective strategies to those who most need them.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 QJMHome page
A. Brown, J. George, M.J. Murphy, and A. Struthers
Could BNP screening of acute chest pain cases lead to safe earlier discharge of patients with non-cardiac causes? A pilot study
QJM, December 1, 2007; 100(12): 755 - 761.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K Chatha, M Alsoud, M J Griffiths, A Elfatih, K Abozguia, R C Horton, S J Dunmore, and R Gama
B-type natriuretic peptide in reversible myocardial ischaemia.
J. Clin. Pathol., November 1, 2006; 59(11): 1216 - 1217.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.